先健科技(01302)：G-iliacTM Pro髂动脉覆膜支架系统获得中国国家药品监督管理局的正式注册批准

Core Viewpoint - The approval of the G-iliacTM Pro iliac artery stent system marks a significant advancement in the company's product offerings, enhancing its position in the minimally invasive treatment of aortic diseases and providing improved solutions for iliac artery reconstruction [1][3]. Group 1: Product Approval and Features - The G-iliacTM Pro stent system received formal registration approval from the National Medical Products Administration of China on January 7, 2026, and is designed for endovascular treatment of abdominal aortic aneurysms combined with iliac artery aneurysms or isolated common iliac artery aneurysms [1]. - The G-iliacTM Pro consists of the G-iliacTM Pro stent and SilverFlowTM Pro stent, maintaining a two-piece combination for safety and convenience, with a low-profile delivery system and ergonomic design for improved operation [2]. Group 2: Clinical Significance and Market Impact - The G-iliacTM system, approved in 2021, was the first commercialized iliac artery bifurcation device in China, addressing a long-standing market gap in endovascular reconstruction of the internal iliac artery [2]. - The company aims to provide a comprehensive solution for aortic minimally invasive treatments, pushing for a more systematic, standardized, and efficient development phase in treating complex aortic diseases [3].